170 related articles for article (PubMed ID: 27734893)
1. Safety concerns blight promising cancer therapy.
Ledford H
Nature; 2016 Oct; 538(7624):150-151. PubMed ID: 27734893
[No Abstract] [Full Text] [Related]
2. Attack of the killer clones.
Scudellari M
Nature; 2017 Dec; 552(7685):S64-S66. PubMed ID: 29293233
[No Abstract] [Full Text] [Related]
3. Cancer immunotherapy.
Bender E
Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244
[No Abstract] [Full Text] [Related]
4. Dendritic cell vaccines for cancer immunotherapy.
Timmerman JM; Levy R
Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291
[TBL] [Abstract][Full Text] [Related]
5. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
Nelson B
Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
[No Abstract] [Full Text] [Related]
6. [New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes].
Kawakami Y
Nihon Naika Gakkai Zasshi; 1998 Dec; 87(12):2536-44. PubMed ID: 9922678
[No Abstract] [Full Text] [Related]
7. Genetic redirection of T cells for cancer therapy.
Westwood JA; Kershaw MH
J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
[TBL] [Abstract][Full Text] [Related]
8. National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment.
Bach PB
N Engl J Med; 2018 Oct; 379(15):1396-1398. PubMed ID: 30110578
[No Abstract] [Full Text] [Related]
9. Cancer vaccines get a shot in the arm.
Cohen J
Science; 1993 Nov; 262(5135):841-3. PubMed ID: 8235605
[No Abstract] [Full Text] [Related]
10. Do no harm.
Nat Biotechnol; 2013 May; 31(5):365. PubMed ID: 23657369
[No Abstract] [Full Text] [Related]
11. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
Peinert S; Kershaw MH; Prince HM
Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
[No Abstract] [Full Text] [Related]
12. BCG as adjuvant immunotherapy for neoplasia.
Hersh EM; Gutterman JU; Mavligit GM
Annu Rev Med; 1977; 28():489-515. PubMed ID: 324372
[No Abstract] [Full Text] [Related]
13. The Cancer Defense.
Weintraub K
Sci Am; 2016 Apr; 314(4):42-51. PubMed ID: 27082190
[No Abstract] [Full Text] [Related]
14. [Cellular immunotherapy as combination partners for the immune checkpoint blockade].
Rössig C
Oncol Res Treat; 2014; 37 Suppl 4():14-5. PubMed ID: 25301192
[No Abstract] [Full Text] [Related]
15. Cancer immunotherapy: Progress and challenges in the clinical setting.
Zarour HM; Ferrone S
Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503
[No Abstract] [Full Text] [Related]
16. Manufacturing genetically modified T cells for clinical trials.
Gee AP
Cancer Gene Ther; 2015 Mar; 22(2):67-71. PubMed ID: 25633481
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: a clinical trial.
Kan N; Ohgaki K; Yamasaki N; Hori T; Nakayama N; Nio Y; Inamoto T; Hikasa Y
Nihon Geka Hokan; 1983 Nov; 52(6):841-53. PubMed ID: 6380446
[No Abstract] [Full Text] [Related]
18. Current developments of immunotherapy in the clinic.
Antonia S; Mulé JJ; Weber JS
Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403
[TBL] [Abstract][Full Text] [Related]
19. New cancer-fighting cells enter trials.
Leslie M
Science; 2018 Sep; 361(6407):1056-1057. PubMed ID: 30213892
[No Abstract] [Full Text] [Related]
20. Immunotherapy of malignant melanoma.
Terry WD
N Engl J Med; 1980 Nov; 303(20):1174-5. PubMed ID: 6999351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
